1. Home
  2. ADT vs GRFS Comparison

ADT vs GRFS Comparison

Compare ADT & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADT Inc.

ADT

ADT Inc.

HOLD

Current Price

$7.97

Market Cap

6.6B

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.71

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADT
GRFS
Founded
1874
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6B
6.2B
IPO Year
2018
2006

Fundamental Metrics

Financial Performance
Metric
ADT
GRFS
Price
$7.97
$8.71
Analyst Decision
Buy
Hold
Analyst Count
4
2
Target Price
$9.25
$10.15
AVG Volume (30 Days)
4.4M
493.4K
Earning Date
02-26-2026
07-28-2022
Dividend Yield
2.76%
1.65%
EPS Growth
N/A
N/A
EPS
0.71
0.64
Revenue
$5,112,859,000.00
$8,821,017,248.00
Revenue This Year
$6.12
$5.36
Revenue Next Year
$3.60
$5.15
P/E Ratio
$10.98
$16.93
Revenue Growth
6.29
7.31
52 Week Low
$7.24
$6.19
52 Week High
$8.94
$11.14

Technical Indicators

Market Signals
Indicator
ADT
GRFS
Relative Strength Index (RSI) 39.45 40.06
Support Level $8.11 $8.79
Resistance Level $8.32 $9.40
Average True Range (ATR) 0.13 0.23
MACD -0.00 -0.07
Stochastic Oscillator 0.00 3.19

Price Performance

Historical Comparison
ADT
GRFS

About ADT ADT Inc.

ADT Inc is a provider of security, interactive, and smart home solutions serving consumer and small business customers in the United States (U.S.). The Company conducts business under the ADT brand name. The company segments include Consumer and Small Business (CSB).

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: